Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1017-1023

  Humphrey, Rachel W ^a   Ohagen, Asa ^b   Davis, David A ^a   Fukazawa, Tominaga ^c   Hayashi, Hideya ^c   Höglund, Stefan ^b   Mitsuya, Hiroaki ^a   Yarchoan, Robert ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c JAPAN ENERGY CORPORATION   (Japan)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; KYNOSTATIN 272; POL PROTEIN; PROTEINASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN PROCESSING; VIRION; VIRUS INFECTIVITY; VIRUS PARTICLE;

EID: 0030894811     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1017     Document Type: Article

References (28)

1. Babe, L. M., and C. S. Craik. 1994. Constitutive production of nonenveloped human immunodeficiency virus type 1 particles by a mammalian cell line and effects of a protease inhibitor on particle maturation. Antimicrob. Agents Chemother. 38:2430-2439.
2. Bugelski, P. J., R. Kirsh, and T. K. Hart. 1994. HIV protease inhibitors: effects on viral maturation and physiologic function in macrophages. J. Leukocyte Biol. 56:374-380.
3. Collier, A., R. Coombs, D. Schoenfeld, R. Bassett, J. Timpone, A. Baruch, M. Jones K. Facey, C. Whitacre, V. McAuliife, H. Friedman, T. Merigan, R. Reichman, C. Hooper, and L. Corey. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N. Engl. J. Med. 334:1011-1017.
4. Danner, S. A., A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, et al. 1995. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333:1528-1533.
5. Davis, D. A., K. Dorsey, P. T. Wingfield, S. J. Stahl, J. Kaufman, H. M. Fales, and R. L. Levine. 1996. Regulation of HIV-1 protease activity through cysteine modification. Biochemistry 35:2482-2488.
6. Dianzani, F., G. Antonelli, O. Turriziani, E. Riva, G. Dong, and D. Bellarosa. 1993. In vitro selection of human immunodeficiency virus type 1 resistant to RO 31-8959 proteinase inhibitor. Antiviral Chem. Chemother. 4:329-333.
7. Erickson-Viitanen, S., J. Manfredi, P. Viitanen, D. E. Tribe, R. Tritch, C. A. D. Hutchison, D. D. Loeb, and R. Swanstrom. 1989. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses 5:577-591.
8. Gottlinger, H. G., J. G. Sodroski, and W. A. Haseltine. 1989. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86:3781-5785.
9. Humphrey, R., B.-Y. Nguyen, K. Wyvill, L. Shay, J. Lietzau, T. Ueno, H. Mitsuya, and R. Yarchoan. 1996. A phase I trial of HIV protease inhibitor KNI-272 in patients with AIDS or symptomatic HIV infection, abstr. Mo.B. 1132. In Abstracts of the International AIDS Meeting, Vancouver, British Columbia, Canada. Transcontinental Printing. Inc., Vancouver, Canada.
10. Johnson, V. A., and R. E. Byington. 1990. Quantitative assays for virus infectivity, p. 71-76. In A. Aldovini and B. D. Walker (ed.), Techniques in HIV research. Stockton Press, New York, N.Y.
11. Kageyama, S., D. T. Hoekzema, Y. Murakawa, E. Kojima, T. Shirasaka, D. J. Kempf, D. W. Norbeck, J. Erickson, and H. Mitsuya. 1994. A C2 symmetry-based HIV protease inhihitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro. AIDS Res. Hum. Retroviruses 10:735-743.
12. Kageyama, S., T. Mimoto, Y. Murakawa, M. Nomizu, H. Ford, T. Shirasaka, S. Gulnik, J. Erickson, K. Takada, H. Hayashi, S. Broder, Y. Kiso, and H. Mitsuya. 1993. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenyl-norstatine. Antimicrob. Agents Chemother. 37:810-817.
13. Kaplan, A., M. Manchester, and R. Swanstrom. 1994. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68:6782-6786.
14. Kaplan, A. H., and R. Swanstrom. 1991. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc. Natl. Acad. Sci. USA 88:4528-4532.
15. Kohl, N., E. Emini, W. Schleif, L. Davis, J. Heimbach, R. Dixon, E. Scolnick, and I. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
16. Krausslich, H.-G., C. Ochsenbauer, A.-M. Traenckner, K. Mergener, M. Facke, H. Gelderblom, and V. Bosch. 1993. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology 192:605-617.
17. Lin, H. J., L. E. Myers, B. Yen-Lieberman, F. B. Hollinger, D. Henrard, C. J. Hooper, R. Kokka, S. Kwok, S. Rasheed, M. Vahey, et al. 1994. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J. Infect. Dis. 170:553-562.
18. Looney, D. J., S. Hayashi, M. Nicklas, R. R. Redfield, S. Broder, F. Wong-Staal, and H. Mitsuya. 1990. Differences in the interaction of HIV-1 and HIV-2 with CD4. J. Acquired Immune Defic. Syndr. 3:649-657.
19. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, F. Sattler, A. La Marca, J. M. Leonard, et al. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
20. Martin, J. 1991. Ro 31-8959/003. Drugs future. 16:210-212.
21. Mergener, K., M. Facke, R. Welker, V. Brinkmann, H. R. Gelderblom, and H. G. Krausslich. 1992. Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology 186:25-39.
22. Mimoto, T., J. Imai, S. Kisanuki, H. Enomoto, N. Hattori, K. Akaji, and Y. Kiso. 1992. Kynostantin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine. Chem. Pharm. Bull. 40:2251-2253.
23. Page, K. A., N. R. Landau, and D. R. Littman. 1990. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J. Virol. 64:5270-5276.
24. Rayner, M. M., B. C. Cordova, R. P. Meade, P. E. Aldrich, P. K. Jadhav, Y. Ru, and P. Y. S. Lam. 1994. DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein. Antimicrob. Agents Chemother. 38:1635-1640.
25. + T-cell counts in HIV-infected patients. Ann. Intern. Med. 124:1039-1050. (See comments.)
26. Tritch, R. J., Y. E. Cheng, F. H. Yin, and S. Erickson-Viitanen. 1991. Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J. Virol. 65:922-930.
27. Vacca, J., B. Dorsey, W. Schleif, R. Levin, S. McDaniel, P. Darke, J. Zugay, J. Quintero, O. Blahy, E. Roth, V. Sardana, A. Schlabach, P. Graham, J. Condra, L. Gotlib, M. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. Emini, and J. Huff. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
28. Witte, O. N., and D. Baltimore. 1978. Relationship of retrovirus polyprotein cleavages to virion maturation studied with temperature-sensitive murine leukemia virus mutants. J. Virol. 26:750-761.